CO-DIAGNOSTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.47 USD | +1.38% |
|
-7.55% | +10.53% |
| 06-14 | Co-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform | CI |
| 05-13 | HC Wainwright Adjusts Price Target on Co-Diagnostics to $2 From $2.50, Maintains Neutral Rating | MT |
| Sales 2024 * | 1.59M 126M | Sales 2025 * | 1.5M 119M | Capitalization | 45.35M 3.59B |
|---|---|---|---|---|---|
| Net income 2024 * | -41M -3.24B | Net income 2025 * | -42M -3.32B | EV / Sales 2024 * | 28.5 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 30.2 x |
| P/E ratio 2024 * |
-1.09
x | P/E ratio 2025 * |
-1.26
x | Employees | 155 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 0% |
More Fundamentals
* Assessed data
More news
Latest transcript on Co-Diagnostics, Inc.
More recommendations
More press releases
| 1 day | +1.38% | ||
| 1 week | -7.55% | ||
| Current month | +40.00% | ||
| 1 month | +33.64% | ||
| 3 months | +25.64% | ||
| 6 months | +21.49% | ||
| Current year | +10.53% |
1 week
1.37
1.59
1 month
1.001.73
Current year
1.001.73
1 year
0.981.89
3 years
0.9811.82
5 years
0.7130.99
10 years
0.6930.99
| Managers | Title | Age | Since |
|---|---|---|---|
Dwight Egan
CEO | Chief Executive Officer | 70 | 17/04/13 |
Brian Brown
DFI | Director of Finance/CFO | 48 | 21/02/21 |
Andrew Benson
IRC | Investor Relations Contact | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Reed L. Benson
LAW | General Counsel | 77 | 31/10/14 |
Richard Serbin
BRD | Director/Board Member | 79 | 30/04/17 |
Dwight Egan
CEO | Chief Executive Officer | 70 | 17/04/13 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.37% | 28 M€ | -4.59% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/06/24 | 1.47 | +1.38% | 152 606 |
| 20/06/24 | 1.45 | -5.23% | 117,767 |
| 18/06/24 | 1.53 | +5.52% | 286,554 |
| 17/06/24 | 1.45 | -8.81% | 203,858 |
| 14/06/24 | 1.59 | -6.47% | 306,549 |
Delayed Quote Nasdaq, June 21, 2024 at 09:00 pm
More quotes
Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Companyâs technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the userâs mobile device.
Calendar
07/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
1.45
USD
Average target price
2
USD
Spread / Average Target
+37.93%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +10.53% | 45.35M | |
| -34.21% | 14.7B | |
| -52.23% | 2.33B | |
| +23.01% | 1.96B | |
| -10.06% | 1.52B | |
| +21.24% | 1.24B | |
| -23.46% | 904M | |
| +1.33% | 784M | |
| -34.13% | 750M | |
| +23.58% | 597M |
- Stock Market
- Equities
- CODX Stock
